Tag Archive for: integrase strand transfer inhibitor

Gender-related differences in safety

Gender-related differences in safety after switching to BIC/TAF/FTC

Human immunodeficiency virus (HIV), one of most serious public health challenges in the world, has already affected approximately 37.6 million people across the globe in 2020 and new infections in 2020 are estimated to be 1.5 million. Bictegravir/ Emtricitabine/ tenofovir (BIC/TAF/FTC) is a fixed-dose combination tablet consisting of an integrase inhibitor and two nucleoside reverse transcriptase inhibitors for the treatment of HIV infection. This HIV medication was approved by the United States Food and Drug Administration (USFDA) in 2018 due to the excellent efficacy outcomes in clinical trials. Real-world safety data of BIC/TAF/FTC was presented at the 18th European AIDS Conference in 2021 and summarised below.

no-difference-in-kidney-transplantation-outcomes-for-HIV-positive-recipients-regardless-of-donor-HIV-status

No difference in kidney transplantation outcomes for HIV-positive recipients regardless of donor HIV status

Human immunodeficiency virus (HIV) has been transformed into a chronic disease to the successful introduction of antiretroviral therapy (ART), and people living with HIV (PWH) now experience morbidity from other chronic conditions, such as kidney, liver, and heart disease.

interim-results-of-a-Phase-2b-3-trial-investigating-a-long-acting-injectable-of-cabotegravir-for-pre-exposure-prophylaxis-of-HIV

Interim results of a Phase 2b/3 trial investigating a long-acting injectable of cabotegravir for pre-exposure prophylaxis of HIV

There is no excerpt because this is a protected post.

comparison-of-the-metabolic-changes-from-the-tango-trial-a-post-hoc-analysis

Comparison of the metabolic changes from the TANGO trial: a post-hoc analysis

There is no excerpt because this is a protected post.